Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:37:35.809Z.
Calculation as of: 2026-10-06T19:37:35.809Z.
Quote observation: 2026-10-06T19:34:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cfadd87817ab9e0f0725aca527bf69eaa76c8d0ff583b2c20c0f03a80ea5973c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2021-07-28.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Minerva Neurosciences, Inc.
Market Cap
$160.50M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$162.23M
EV/EBITDA Ratio
N/A
TTM Avg
8.39x
3Y Avg
66.32x
5Y Avg
66.32x
Market Cap
$159.22M
EV/EBITDA Ratio
N/A
TTM Avg
159.13x
3Y Avg
159.13x
5Y Avg
159.13x
Market Cap
$165.17M
EV/EBITDA Ratio
10.40x
TTM Avg
86.42x
3Y Avg
168.75x
5Y Avg
173.55x
Market Cap
$156.62M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | $160.50M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $162.23M | N/A | 8.39x | 66.32x | 66.32x |
| PepGen Inc. (PEPG)vs › | $159.44M | N/A | N/A | N/A | N/A |
| Quanterix Corporation (QTRX)vs › | $162.44M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | N/A | 159.13x | 159.13x | 159.13x |
| Nkarta, Inc. (NKTX)vs › | $164.91M | N/A | N/A | N/A | N/A |
| OptimizeRx Corp. (OPRX)vs › | $165.17M | 10.40x | 86.42x | 168.75x | 173.55x |
| Inogen, Inc. (INGN)vs › | $156.90M | N/A | 29.09x | 58.55x | 59.27x |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | N/A | N/A | N/A | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $166.54M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2021-07-28 | 0.22x |
| 2021-07-26 | 0.10x |
| 2021-07-23 | 0.41x |
| 2021-07-22 | 0.79x |
| 2021-07-21 | 1.17x |
| 2021-07-20 | 0.92x |
| 2021-07-19 | 0.60x |
| 2021-07-16 | 0.35x |
| 2021-07-15 | 0.92x |
| 2021-07-14 | 0.85x |
| 2021-07-13 | 1.23x |
| 2021-07-12 | 2.11x |
| 2021-07-09 | 2.36x |
| 2021-07-08 | 2.36x |
| 2021-07-07 | 2.74x |
| 2021-07-06 | 2.80x |
| 2021-07-02 | 2.80x |
| 2021-07-01 | 2.93x |
| 2021-06-30 | 2.80x |
| 2021-06-29 | 3.12x |
| 2021-06-28 | 3.37x |
| 2021-06-25 | 3.75x |
| 2021-06-24 | 3.81x |
| 2021-06-23 | 3.69x |
| 2021-06-22 | 3.69x |
| 2021-06-21 | 4.19x |
| 2021-06-18 | 4.76x |
| 2021-06-17 | 5.07x |
| 2021-06-16 | 5.83x |
| 2021-06-15 | 5.83x |
| 2021-06-14 | 6.83x |
| 2021-06-11 | 6.46x |
| 2021-06-10 | 7.53x |
| 2021-06-09 | 7.02x |
| 2021-06-08 | 7.34x |
| 2021-06-07 | 7.27x |
| 2021-06-04 | 6.46x |
| 2021-06-03 | 6.58x |
| 2021-06-02 | 6.77x |
| 2021-06-01 | 6.90x |
| 2021-05-28 | 6.77x |
| 2021-05-27 | 6.83x |
| 2021-05-26 | 7.40x |
| 2021-05-25 | 6.71x |
| 2021-05-24 | 7.27x |
| 2021-05-21 | 7.78x |
| 2021-05-20 | 8.15x |
| 2021-05-19 | 8.15x |
| 2021-05-18 | 10.29x |
| 2021-05-17 | 9.16x |
| 2021-05-14 | 6.64x |
| 2021-05-13 | 5.13x |
| 2021-05-12 | 40.98x |
| 2021-05-11 | 33.73x |
| 2021-05-10 | 34.97x |
| 2021-05-07 | 34.35x |
| 2021-05-06 | 34.15x |
| 2021-05-05 | 36.84x |
| 2021-05-04 | 35.60x |
| 2021-05-03 | 38.70x |
| 2021-04-30 | 36.84x |
| 2021-04-29 | 37.88x |
| 2021-04-28 | 39.33x |
| 2021-04-27 | 39.95x |
| 2021-04-26 | 39.95x |
| 2021-04-23 | 39.95x |
| 2021-04-22 | 39.74x |
| 2021-04-21 | 39.74x |
| 2021-04-20 | 37.46x |
| 2021-04-19 | 37.46x |
| 2021-04-16 | 40.16x |
| 2021-04-15 | 39.53x |
| 2021-04-14 | 37.88x |
| 2021-04-13 | 37.67x |
| 2021-04-12 | 37.67x |
| 2021-04-09 | 42.85x |
| 2021-04-08 | 44.30x |
| 2021-04-07 | 42.23x |
| 2021-04-06 | 44.71x |
| 2021-04-05 | 47.20x |
| 2021-04-01 | 49.07x |
| 2021-03-31 | 48.03x |
| 2021-03-30 | 48.44x |
| 2021-03-29 | 43.89x |
| 2021-03-26 | 48.03x |
| 2021-03-25 | 47.82x |
| 2021-03-24 | 46.99x |
| 2021-03-23 | 50.10x |
| 2021-03-22 | 49.27x |
| 2021-03-19 | 50.72x |
| 2021-03-18 | 51.76x |
| 2021-03-17 | 53.21x |
| 2021-03-16 | 53.42x |
| 2021-03-15 | 56.32x |
| 2021-03-12 | 56.73x |
| 2021-03-11 | 55.70x |
| 2021-03-10 | 51.76x |
| 2021-03-09 | 51.97x |
